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Human papillomavirus (HPV) infection in cases of
squamous cell carcinoma of the oropharynx is a pow-
erful predictive and prognostic biomarker. We de-
scribe how the use of next-generation sequencing can
provide a novel method for the detection of HPV in
DNA isolated from formalin-fixed paraffin-embedded
tissues. Using this methodology in a cohort of 44 head
and neck tumors, we identified the samples that con-
tained HPV sequences, the viral subtype involved, and
a direct readout of viral load. Specificity of HPV detec-
tion by sequencing compared to traditional detection
methods using either PCR or p16 immunohistochem-
istry was 100%. Sensitivity was 50% when either com-
pared to PCR [confidence interval (CI)  29% to 71%]
or 75% when compared to p16 (CI  47% to 91%). In
addition, we demonstrate the ability of next-genera-
tion sequencing to detect other HPV subtypes that
would not have been detected by traditional methods,
and we demonstrated the ability to apply this method
to any tumor and any virus in a panel of eight human
cancer cell lines. This methodology also provides a
tumor genomic copy number karyogram, and in the
samples analyzed here, a lower level of chromosome
instability was detected in HPV-positive tumors com-
pared to HPV-negative tumors, as observed in previ-
104ous studies. Thus, the use of next-generation sequenc-
ing for the detection of HPV provides a multiplicity of
data with clinical significance in a single test. (J Mol
Diagn 2012, 14:104-111; DOI: 10.1016/j.jmoldx.2011.10.003)
The role of human papillomavirus (HPV) infection is well
established in the etiology of a range of tumors including
cervical, anogenital, and oropharyngeal (OP) carcino-
mas; for others, for example in colon carcinoma and in
lung, its role is less certain. For a subset of OP cancers,
there is convincing evidence that HPV is the carcinogenic
agent, rather than smoking and/or excess alcohol con-
sumption, which are causative factors with other squa-
mous cell carcinomas (SCC) of the head and neck. The
presence of HPV sequences in the tumor genome identifies
a patient group with an improved treatment response and
better prognosis.1,2 The difference in survival is sufficiently
marked that it has been suggested that patients with OP
SCC should be stratified according to their HPV status and
their treatment de-escalated to reflect this status.3 If HPV
status is to be used to guide treatment decisions, its accu-
rate assessment will be of critical importance, and themeth-
ods for its detection will require full evaluation before ac-
ceptance as a routine clinical test.
Because HPV infection is not entirely tumor cell–spe-
cific, a test of its role in the carcinogenic process is
essential. This can involve the direct detection of viral
transcripts of the HPV transforming genes E6 and E7 or
the effect of these transcripts on the host cell, eg, detec-
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CDKN2A) by immunohistochemistry (IHC). A recent
study of 237 cases of OP SCC, of which 78% were HPV-
positive, concluded that p16 IHC alone is sufficient for
risk stratification.4 However, not all p16-positive biopsies
from the oropharynx are associated with integration of
HPV genomes,5–7 thus it is likely that a combination of
assays will be required to ensure the sensitivity and spec-
ificity required of a test on which clinical planning de-
pends. To achieve this, Smeets et al8 defined an algo-
rithm to determine HPV status by using p16 IHC, followed
by PCR with HPV generic primers, and this procedure
has been widely endorsed.9 A similar approach has been
tested in a prospective collection of 256 head and neck
SCCs where p16 IHC and HPV-16 ISH were used.10
Besides viral subtype and biological activity, viral copy
number may also be important in predicting clinical out-
come. In two recent studies, viral copy number, mea-
sured by a sensitive quantitative test was significantly
associated with a better response to induction chemo-
therapy and chemoradiotherapy,11 as well as disease-
specific survival and overall survival.12
We have recently demonstrated that even at very low
genome coverage, next-generation sequencing (NGS)
can provide genomic copy number enumeration from nano-
gram quantities of DNA isolated from routine diagnostic
formalin-fixed paraffin-embedded (FFPE) tissue.13 We have
applied this approach here to an archival series of head and
neck SCC tumors for the simultaneous detection of the HPV
genome and genomic copy number enumeration, and
compared it to traditional detection methods.
Materials and Methods
Cell Lines for DNA Extraction
Cell lines were used as a measure of the specificity of
detection of HPV by NGS. LUDLU-1 is derived from lung
SCC, and AGLCL is its matching B lymphoblast cell
line.14 NCI-H1437 is derived from lung adenocarcinoma,
and similarly, B1437 is its matching B lymphoblast cell
line. HONE-1 is derived from nasopharyngeal SCC15 and
was a gift from Dr. Maria Kost-Alimova. A549 is derived
from alveolar cell carcinoma.16 SiHa and CaSki are both
derived from cervical SCC and are known to contain
HPV.17,18 These were a gift from Dr. Nicholas Colman.
KYSE-70 is derived from esophageal SCC.19 All cell lines
were cultured using standard cell culture techniques.
DNA was prepared from 1 to 7  106 cells by standard
phenol-chloroform extraction.
Patient Samples
Patients included in this study were diagnosed with
SCC of the head and neck, and treated with chemora-
diotherapy at the Yorkshire Cancer Centre between 2003
and 2006 (ethics approval: REC07/Q1206/30). In total, 52
patient samples were identified for this study. The patient
demographics are summarized in Supplemental Table
S1 (available at http://jmd.amjpathol.org). Of the 52 pa-
tient samples identified, 44 were suitable for inclusion inthe study based on the presence of SCC in their FFPE
block. Of the 44 tumors sampled, there were 20 OP, 12
laryngeal, 8 hypopharyngeal, and 4 oral samples.
For DNA extraction, a hematoxylin and eosin (H&E)-
stained slide was cut from each FFPE block and tumor
areas marked by a pathologist. Ten 7-m sections were
then serially cut onto plain glass slides, and after dewax-
ing and rehydration of the sections, the tumor tissue was
macrodissected using a sterile scalpel blade and the
marked H&E slide as a guide. DNA extraction was per-
formed on dissected tissue using the QIAamp DNA mini
kit (Qiagen, Crawley, UK) according to the manufactur-
er’s instructions and quantified using the Nanodrop-8000
(Thermo Scientific, Loughborough, UK) and the Quant-iT
dsDNA BR assay (Life Technologies, Paisley, UK).
HPV Detection by PCR
Detection of HPV sequences was performed on patient
samples in two separate PCRs using two different sets of
primers: a generic set (GP5/GP6) widely used to
detect all HPV subtypes20 (F: 5=-TTTGTTACTGTGG-
TAGATACTAC-3=, R: 5=-GAAAAATAAACTGTAAATCAT-
ATTC-3=) and an HPV16-specific set21 (F: 5=-TCAAAA-
GCCACTGTGTCCTG-3=, R: 5=-CGTGTTCTTGATGATCT-
GCA-3=). A control PCR of a 79-bp fragment of -globin
(HBB) was also performed (F: 5=-GGATCCTTCTCTTGT-
GTTGG-3=, R: 5=-CTACCATTGGAAAAGCAACC-3=). Re-
actions containing 1 Amplitaq Gold PCR buffer, 3
mmol/L magnesium chloride, 1 mol/L of each primer,
0.4 mmol/L deoxynucleotide triphosphates (dNTPs), 2 U
of Amplitaq Gold DNA polymerase (Life Technologies), and
2 ng of DNA were prepared in a volume of 25 L. PCR
conditions were: 9 minutes at 93°C; 40 cycles of 94°C for 20
seconds, 53°C for 20 seconds, and 72°C for 40 seconds;
then 72°C for 7 minutes. PCR products were visualized on
4% agarose gels and scored for the presence or ab-
sence of bands of 79 bp (HBB), 150 bp (generic HPV
PCR), and 120 bp (HPV-16 PCR).
Immunohistochemistry of p16
Immunohistochemistry for detection of p16 protein expres-
sion as a marker for HPV infection in patient samples was
performed using the CINtec Histology Kit (MTM Laborato-
ries, Heidelberg, Germany) using half volumes for all steps
and following the manufacturer’s instructions. The primary
antibody is a monoclonal mouse anti-human p16INK4a an-
tibody, Clone E6H4. An FFPE bladder tumor with high p16
expression was used as a positive control, and a normal
FFPE tonsil as a negative control. Two pathologists blinded
to HPV status assessed the staining, and a score of positive
was recorded when moderate-to-strong staining over
70% of the tumor cells was observed.
Sequencing and Alignment
Libraries were prepared for Illumina sequencing from
each DNA sample using 100 ng to 1 g of DNA, following
recently described protocols.13 Equal amounts of each
library passing quality control were multiplexed to 10
first as t
ber of
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taining 70 bp of genomic DNA sequence and 6 bp of
tagged adapter. Reads were sorted into files according
to their unique tag and stripped of the tag sequence,
aligned to both the human reference genome (UCSC
version hg19, http://genome.ucsc.edu, last accessed
April 26, 2010) and to either all known HPV subtypes
(patient samples) or all known viral genomes (cell lines
only) downloaded from the National Center for Biotech-
nology Information (http://www.ncbi.nlm.nih.gov/genomes/
GenomesHome.cgi?taxid10239, last accessed Novem-
ber 26, 2010) using the Burrows-Wheeler Aligner22 and
alignments stored in SAM format.23 See Table 1 for the
range of human and viral reads obtained for each sample.
Whole-Genome Copy Number Analysis
Copy number for the human DNA was calculated as
Table 1. Summary of Sequencing Results
Sample ID
HPV
reads Human reads
Read density
per read
CaSki 2862 1,706,022 3.52
SiHa 5 877,220 6.84
NCI-H1437 0 463,326 12.95
BL1437 0 580,030 10.34
LUDLU1 0 2,533,814 2.37
AGLCL 0 5,001,596 1.20
A549 0 3,724,820 1.61
HONE-1 13 3,198,312 1.88
DH001 37 956,486 6.27
DH002 0 1,160,065 5.17
DH004 84 667,239 8.99
DH007 0 1,439,606 4.17
DH008 0 1,016,359 5.90
DH009 0 871,248 6.89
DH013 0 1,362,793 4.40
DH014 0 1,337,389 4.49
DH018 0 936,348 6.41
DH020 103 791,362 7.58
DH021 0 648,902 9.25
DH022 0 611,540 9.81
DH023 0 1,752,721 3.42
DH025 0 358,573 16.73
DH026 0 1,386,393 4.33
DH028 122 1,889,202 3.18
DH030 67 547,974 10.95
DH032 5 1,357,961 4.42
DH033 92 1,535,954 3.91
DH034 1 440,355 13.63
DH035 0 2,004,696 2.99
DH036 0 300,766 19.95
DH039 0 68,384 87.74
DH040 0 1,038,324 5.78
DH042 0 529,936 11.32
DH045 78 1,369,241 4.38
DH046 0 1,444,389 4.15
DH047 112 1,326,000 4.52
DH048 0 309,096 19.41
DH050 0 1,742,778 3.44
DH051 0 833,039 7.20
DH052 0 555,067 10.81
Results for cell lines are shown at the top, followed by patient sample
From the number of human reads, and assuming a diploid genome, the
of 7.9 kb and the density of reads, the amount of HPV genome is given,
Finally, the detectable viral load with 95% confidence given the total numpreviously described.13 Briefly, human reads were sortedby chromosome and position. The ratio of test to control
reads in windows of equal size averaging 400 reads was
calculated across the genome. The control sample was
constructed from a pool of 20 normal British individuals
downloaded from the 1000 Genomes Project24 (ftp://
ftp.1000genomes.ebi.ac.uk/vol1/ftp, last accessed, March
03, 2011). Frequency plots comparing HPV-positive and
-negative tumors were drawn by counting how many
samples exceeded a 0.25 log2 tumor/normal ratio
along the genome (HPV status determined by sequence
detection).
HPV Detection and Load Measurements by
Sequencing
To measure HPV viral load, the number of reads align-
ing to the human and HPV genomes were counted. To
avoid false positives, only reads aligning with the highest
Kb HPV sequence HPV viral load
Detectable viral
load
10065.52 1273.47 1.33
34.20 4.33 2.59
0.00 0.00 4.91
0.00 0.00 3.92
0.00 0.00 0.90
0.00 0.00 0.45
0.00 0.00 0.61
24.39 3.09 0.71
232.10 29.36 2.38
0.00 0.00 1.96
755.35 95.57 3.41
0.00 0.00 1.58
0.00 0.00 2.24
0.00 0.00 2.61
0.00 0.00 1.67
0.00 0.00 1.70
0.00 0.00 2.43
780.93 98.80 2.88
0.00 0.00 3.51
0.00 0.00 3.72
0.00 0.00 1.30
0.00 0.00 6.35
0.00 0.00 1.64
387.47 49.02 1.20
733.61 92.82 4.15
22.09 2.80 1.68
359.39 45.47 1.48
13.63 1.72 5.17
0.00 0.00 1.13
0.00 0.00 7.56
0.00 0.00 33.27
0.00 0.00 2.19
0.00 0.00 4.29
341.80 43.24 1.66
0.00 0.00 1.58
506.79 64.12 1.72
0.00 0.00 7.36
0.00 0.00 1.31
0.00 0.00 2.73
0.00 0.00 4.10
ach sample, the numbers of viral and human reads obtained are given.
of reads in kb per read is calculated. Given a known HPV genome size
he kb of viral sequence, then as the number of viral copies or viral load.
reads is calculated.kb
s. For e
densityBurrows-Wheeler Alignment mapping score of 37 that did
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estimate the minimum number of viral genomes from the
observed number of viral reads. If we had an infinitely
large number of reads, the fraction, or expected fre-
quency of viral reads would be:
NVIG
VGS
HGS
,
where VGS  viral genome size, HGS  human genome
size, and NVIG  number of viral genomes.
In a sample of N reads, the expected number of reads is:
 roundN
or
 roundNNVIG VGSHGS.
For example, if we found 66 viral reads of a total of 1
million, the number of viral genomes would be 66
reads/(1 million reads  7900-bp viral genome/6 bil-
lion–bp human genome)  50.
The chance of detecting a viral genome of a known
size among reads from a human genome can be calcu-
lated for various sequence depths (Figure 1). Because
reads are randomly distributed, we expect the number of
observed reads k to follow a Poisson distribution.
Pk, 
ke
k!
We can now find the value of  such that
P0, 
ie, for which  we would observe one or more reads in
Figure 1. The statistically detectable viral load for increasing numbers of
reads. The lines indicate the minimum detectable numbers of viruses per cell
for different read numbers for three different probabilities.1   percentage of cases. Similarly, we could find thevalue of  for any value of k and calculate the cumulative
probability of observing k or fewer reads.

i0
k
Pi, 
In this way, we can estimate the number of virus genomes
that would produce the observed reads. We can see from
Figure 1, for example, that if a sample has 10 viral copies
per cell, approximately 250,000 reads are needed to
detect at least one viral sequence with a 95% confidence.
Similarly, 500,000 reads are needed to detect 5 viral
copies per cell and 1 million reads can detect 3 viral
copies per cell at 95% confidence. The same numbers of
reads can detect smaller viral loads with correspondingly
smaller probabilities. The number of detectable human
reads for each sample can be seen in Table 1. Episomal
and integrated viral genomes are indistinguishable at this
low read depth.
Results
HPV Detection by PCR
HPV sequence detection by PCR was performed on 44
patient DNA samples (see Supplemental Table S2 at
http://jmd.amjpathol.org). In the HBB control PCR, 38 of
44 (86%) samples were successfully amplified. In the
HPV PCRs, 23 of 44 (52%) samples were scored as
HPV-positive using generic primers (GP5/GP6) and 16
of 44 (36%) samples scored as positive using HPV-16–
specific primers, 15 of which were also positive with the
generic primers. Two of the samples that were scored as
positive for HPV-16 scored as negative for the control
HBB PCR.
p16 Expression by Immunohistochemistry
Detection of p16 protein expression by immunohisto-
chemistry was performed on 44 patient DNA samples
(see Supplemental Table S2 at http://jmd.amjpathol.org).
Results were obtained for all but one sample (DH052),
which had no tumor cells remaining on the slide and
therefore could not be scored. Protein expression of p16
was scored as positive in 16 of 43 (37%) patient samples.
Samples positive for p16 were also positive by at least
one PCR for HPV, except for DH043, which had strong
specific staining for p16 but was negative by both PCRs
and also could not be sequenced.
HPV Detection by NGS
As a measure of the specificity of the technique, and to
demonstrate its capacity to detect viral sequences other
than HPV, a number of cell lines were sequenced to a
similar depth and the reads aligned to all known viral
genomes. As several viral genomes have repetitive ele-
ments and/or resemble other viruses and other bacterial
and eukaryotic genomes, all sequences aligning to a viral
genome were put into a BLAST search against all known
nucleotide sequences. Only those reads where the Bur-
uencing
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were considered (Table 1).
The HPV-positive cell lines SiHa and CaSki contained
sequences from HPV-16 only, with viral loads of 4 and
1273 copies per cell, respectively. The lung tumor cell
lines LUDLU-1, NCI-H1437, and A549 were all free of
viral sequence, whereas the counterpart B-cell lines
AGLCL and BL1437 had high levels of Epstein-Barr virus
infection as expected. The nasopharyngeal cell line
HONE-1 had a previously unknown low level (three cop-
ies per cell) of HPV-18.
Patient Samples
Sequencing libraries were prepared from all 44 sam-
ples, and 31 (70%) of these yielded a sufficient quan-
tity of library for multiplexed NGS (see Supplemental
Table S2 at http://jmd.amjpathol.org). Of the 13 sam-
ples that failed, 6 were positive by at least one other
method. The age of the FFPE block did not correlate
with failure of library preparation. The amount of tissue
sampled and the amount of template DNA used for
library preparation was lower for fails but not signifi-
cantly. Using the HBB PCR as a quality control mea-
sure, a PCR product was detected less often for failed
samples (69% versus 94%), but again, this was not
Table 2. Summary of Sequenced Samples
Patient ID
Tumor
location
PCR
HBB
PCR HPV
GP5/GP6
P
HP
DH001 OP  
DH004 OP  
DH007 OP  
DH008 OP  
DH020 OP  
DH021 OP  
DH022 OP  
DH028 OP  
DH030 OP  
DH033 OP  
DH034 OP  
DH035 OP  
DH047 OP  
DH036 HYP  
DH039 HYP  
DH045 HYP  
DH048 HYP  
DH052 HYP  
DH023 ORAL  
DH032 ORAL  
DH040 ORAL  
DH051 ORAL  
DH002 L  
DH009 L  
DH013 L  
DH014 L  
DH018 L  
DH025 L  
DH026 L  
DH042 L  
DH046 L  
HPV status results from all detection methods are shown for samples t
oropharyngeal (OP), hypopharyngeal (HYP), oral (ORAL), and laryngea
detected in the sample and calculated viral load by next-generation seq
NA, not available.significant.The number of reads obtained by sequencing and
the resulting viral load calculations are listed in Table
1. The mean number of reads obtained from patient
samples was 1,018,465 (range, 68,384 to 2,004,696).
The median viral load detectable at 95% confidence
was 2.31 (range, 1.13 to 33.27). HPV sequence was
detected in 10 of 31 samples with viral loads ranging
from 1 to 98 HPV genomes per human genome (Table
2). PCR and p16 IHC results were concordant in nine of
these samples; however, one sample (DH032) had
HPV detected by NGS, but not by either PCR or IHC.
The HPV sequences detected by sequencing in this
sample were specific to HPV-61. Specificity of HPV
detection by sequencing compared to PCR or p16 IHC
was 100% [confidence interval (CI)  76% to 100%
and 82% to 100%, respectively]. Sensitivity was 50%
compared to PCR detection (CI  29% to 71%) or 75%
when compared to p16 IHC (CI  47% to 91%). For
comparison, p16 IHC had 100% specificity (CI  76% to
100%) and 67% (CI  44% to 84%) sensitivity compared
to PCR detection.
Whole-Genome Copy Number Analysis
Visual examination of the 31 individual patient genomic
IHC
p16
Sequencing
HPV
Sequencing
HPV type
Sequencing
HPV load
  HPV-16 29
  HPV-16 96
  0
  0
  HPV-16 99
  0
  0
  HPV-16 49
  HPV-16 93
  HPV-16 45
  HPV-16 2
  0
  HPV-16 112
  0
  0
  HPV-16 78
  0
  0
  0
  HPV-61 3
  0
NA  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
successfully sequenced (n  32). Samples are listed by tumor location:
ssay results are shown as positive () or negative (). HPV subtypes
are also shown.CR
V-16































hat were
l (L). Acopy number traces (data not shown) revealed, in gen-
played a
tumors
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tumors (n  10) compared to HPV-negative tumors (n 
21). By comparing the frequency diagrams of the two
groups, locus-specific differences in copy number can
also be seen (Figure 2). In the HPV positives, there is a
lower frequency of loss at chromosome 3p and 8p, and a
lower frequency of gain of 5p and 8q. Loss of chromo-
some 3p was the copy number variation most frequently
detected as different between HPV-negative tumors (11
of 21) and HPV-positive tumors (1 of 10).
Discussion
Here, we describe the use of NGS as amethod for detection
of HPV in FFPE samples from head and neck SCCs, and
demonstrate the power of this method to provide a digital
readout of viral load, viral subtype, and a tumor karyogram
in a single test. By screening a panel of cell lines for all
known viruses, we have shown the potential for this tech-
nique to be applied to other virus-associated cancers and
diseases. Using NGS, we detected HPV sequences in 61%
of OP samples, a similar frequency to that found in a larger
study.4 We have shown that this method has a high sensi-
tivity and specificity for the detection of HPV, comparable to
other methods tested here and in previous studies.8,10 We
detected HPV-61 in one oral tumor that was not detected by
any other method, and a previous study has shown that this
subtype cannot be amplified with the generic primers
Figure 2. Frequency of genomic gain and loss for HPV-positive and HPV-ne
tumor samples with a copy number log2 ratio of 0.25 is measured and dis
HPV detected by sequencing (NGS HPV-positive, n  10) are compared to(GP5/GP6).25 Although the oncogenic potential of thissubtype is not known, it has been previously found at high
levels in cervical and vaginal specimens.26,27 The ability to
detect all HPV subtypes using NGS could potentially lead to
a more accurate prevalence of this virus and better under-
standing of its role in the etiology of epithelial cancers.
In the PCR methods tested, there were 6 of 44 samples
positive for HPV but negative for p16 IHC, suggesting
that these methods may be overly sensitive, a phenom-
enon also reported in the study by Smeets et al.8 In
comparison, all samples positive for HPV-16 by sequenc-
ing were also p16 positive, suggesting a much better
specificity for the virus. It is possible for many clinical
applications that the sensitivity of the test is not as crucial
as specificity for this virus, and this is where sequencing
is at an advantage. It has been shown both in the cervix28
and in the oropharynx29 that only the presence of high
copies of the virus was relevant in the patient’s prognosis.
For sequencing, the number of reads obtained per sam-
ple determines the sensitivity of the method. We have
shown that a minimum of 2 million reads per sample are
required to predict a minimum viral load of one HPV
genome per cell in a pure tumor cell population at 95%
confidence. Although we did not produce that read num-
ber for the majority of our samples, it would be easily
achievable with a lower level of sample multiplexing (eg,
5 samples per lane instead of 10).
In this study, we used FFPE blocks that were at least 5
years old because they are a component of an ongoing
umor groups. For each position along the genome, the proportion of patient
s frequency of gain (red) or loss (green). Here, patient tumor samples with
with no HPV sequence detected (NGS HPV-negative, n  21).gative tlarger study in which survival data are required. None-
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was not related to age of block or DNA quantity used.
Once a sequencing library has been made, it is easy to
predict which will produce good sequence data by ex-
amining the quality control data from the finished librar-
ies.13 However, it has not yet proved possible to predict
which DNA samples will produce good libraries. In time,
the potential speed, efficiency, and low cost13 of this
methodology means it could be applied to clinical sam-
ples as part of their diagnosis, and the use of newer FFPE
tissue has been shown to improve success rates for
molecular assays.30,31 Also, since the analysis simulta-
neously measures tumor and viral gene copy number, a
karyogram of genomic copy number is produced for
each tumor sample. Such information has been shown to
be useful in predicting outcomes in other cancers3233 For
oropharyngeal cancer, copy number signatures have
been shown to distinguish HPV-positive from HPV-nega-
tive samples,34 and it has been proposed that both HPV
status and the level of chromosome instability should
contribute to the classification of head and neck SCC.3
This study demonstrates the utility of NGS for the detec-
tion of viruses in human samples and its potential to
contribute a multiplicity of data for use as a diagnostic,
prognostic or stratification tool in the clinic and in future
clinical trials.
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